HELPNYSECybin Inc. Common Stock

HELP price activity

Last Price

Change (24hr)

USD (%)

Volume

Volume (4w avg)

Previous Close

N/A

Last Trade

HELP price performance

8,82%

55,43%

53,91%

YTD

81,94%

HELP price fundamentals

N/A

Shares Issued

N/A

Earnings Per Share (EPS)

N/A

Dividends Per Share (DPS)

N/A

P/E Ratio

Price market cap

Market cap

N/A

US-NYSE rank

N/A

Sector Rank

N/A

HELP details

View company website

View US-NYSE Official Page

Dividendos de HELP

Ver mais

quote.marketSignals

Mais formas de descobrir

Ver notícias de United States Descubra sinais de NYSE Ver todas as ações de NYSE Ver todos os ETFs de NYSE

Cybin Inc. Common Stock (US-NYSE: HELP)

Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.

Price: $12.59

Sector: Healthcare — Biotechnology